|
|
Gynecologic CancerClick on the protocol number to learn more about that clinical trial.
|  A Phase II Evaluation of Ixabepilone in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus | |
| | A Phase II Evaluation of ABT-888 (IND #77840), Topotecan and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix | |
| | A Phase II Evaluation of Ixabepilone in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus | |
| | A Phase II Randomized, Double Blinded Evaluation of Oral Everolimus (RAD001) Plus Bevacizumab vs. Oral Placebo Plus Bevacizumab in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | |
| | A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 monthly cycles of Single Agent Paclitaxel or Xyotax (TM) (CT-2103) (IND# 70177), Versus no Treatment Until Documented Relapse in Women with Advanced Ovarian or Primary Peritoneal Cancer Achieve a Complete Clinical Response to Primary Plantum/Taxane Chemotherapy | |
| | A Phase III Randomized Controlled Clinical Trial Of Carboplatin And Paclitaxel Alone Or In Combination With Bevacizumab (Nsc #704865, Ind #7921) Followed By Bevacizumab And Secondary Cytoreductive Surgery In Platinum-Sensitive, Recurrent Ovarian, Fallopian Tube And Peritoneal Primary Cancer | |
| | A Phase II Evaluation of Brivanib (IND #108417) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix | |
| | A Phase II Evaluation of BIBF 1120 (IND #113086) in the Treatment of Recurrent or Persistent Endometrial Carcinoma | |
| | A Phase II Trial of AMG 386 (IND #111071), a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients with Persistent/Recurrent Carcinoma of the Endometrium | |
| | A Phase II Evaluation of Pazopanib (NSC #737754, IND #75648) In the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus | |
| | A Prospective, Longitudinal Study of YKL-40 in Patients with FIGO Stage III or IV Invasive Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Undergoing Primary Chemotherapy | |
| | A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-only Recurrence of Carcinoma of the Uterine Corpus | |
| | A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma | |
| | A Randomized Phase III Evaluation of Docetaxel and Gemcitabine Plus G-CSF with Bevacizumab versus Docetaxel and Gemcitabine Plus G-CSF with Placebo in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus | |
| |
A Phase II Evaluation of SU11248 (Sunitinib Malate) in the Treatment of Persistent or Recurrent Clear Cell Ovarian Carcinoma | |
| | A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma | |
| | A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer | |
| | A Randomized Phase III trial of Paclitaxel plus Carboplatin versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients with Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus or Ovary | |
| | A Randomized Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination with Carboplatin with or without Concurrent and Consolidation Bevacizumab (NSC #704865, IND #7921) in the Treatment of Primary Stage III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer | |
| |
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy | |
| | A Phase III Evaluation of Temsirolimus (CCI-779) in Combination with Carboplatin and Paclitaxel Followed by Temsirolimus (CCI-779) Consolidation as First Line Therapy in the Treatment of Stage III-IV Clear Cell Carcinoma of the Ovary | |
| | Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy | |
|
|
|
|
| Login |
Print this page
© OzarksCancerResearch.org - All Right Reserved. | Powered by Winnovate w360™ |